ZennCell Appoints Lee Seong-ho as Co-CEO

Separation of Management and R&D with Full-Scale New Drug Clinical Trials
New Business and IPO Expected to Accelerate

[Asia Economy Reporter Park Hyungsoo] Genencell held an extraordinary general meeting of shareholders on the 3rd and newly appointed Lee Seongho as co-CEO.

CEO Lee Seongho graduated from Seoul National University with a degree in Biology (currently the Department of Life Sciences) and has served in the Strategic Planning Office and Ethics Management Office of Daehan Electric Wire Group, the Strategic Planning Department of Medipost, and as Director of Management at Olipass.

Genencell plans to promote mid- to long-term management strategies for becoming a global company centered on the new CEO Lee Seongho. They also plan to accelerate new business development, investment attraction, and initial public offering (IPO).

The existing CEO Jeong Yongjun will focus his capabilities on the research and development sector as clinical trials for new drugs such as the shingles treatment and COVID-19 treatment enter full swing, while continuing his role as co-CEO.

Genencell has established a strategy to separate management and research and development sectors to increase efficiency and strengthen responsibility as the ongoing new drug development enters its main track.

In July, Genencell received approval from the Ministry of Food and Drug Safety for phase 2 clinical trials of the natural product-based candidate substance ‘ES16001’ for shingles, which is currently underway. The COVID-19 treatment has completed phase 2 trials in India and is preparing to apply for global phase 2b/3 clinical trials.

This content was produced with the assistance of AI translation services.